Donate Toggle Menu

David participated in a Phase 2 clinical study that evaluated a personalized cancer immunotherapy in combination with a standard targeted drug therapy, sunitinib.

For more information about immunotherapy, clinical trials or standard treatments for advanced kidney cancer, please contact the Kidney Cancer Association at 1-800-850-9132 or visit

The statements made in this video are those of the patient and physician, based on their own experiences with an investigational immunotherapy during a clinical study. Please note, the results described in this video testimonial may not be the same for everyone participating in clinical trials.